Kos Pharmaceuticals ( KOSP) named John J. Howarth vice president of investor relations and corporate affairs. The Cranbury, N.J., company said Howarth "brings to Kos a wealth of knowledge, experience and leadership in investor relations spanning more than 22 years in the health care industry." Indeed, Kos noted that before heading investor relations at Antigenics ( AGEN) and holding a similar job at Elan ( ELN), Howarth spent nearly two decades at Warner-Lambert, now part of Pfizer ( PFE). "During his tenure," Kos said, "Warner-Lambert had a number of significant corporate and product events including the launch of Lipitor, the launch and subsequent recall of Rezulin, as well as significant merger discussions." On Wednesday, shares of Kos fell 66 cents to $60.50.